Trial NCT04471519 ; CTRI/2
Publication Ella R, Lancet Infect Dis, 2021
Primary outcome on the report: The primary outcome was SARS-CoV-2 wild-type neutralising antibody titres and seroconversion rates at 4 weeks after the second dose (day 56).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.